Search
Viridian Therapeutics Inc
VRDNAdd to Watchlist
28.490USD
-0.060-0.21%
Close 11-06 16:00（ET）
3.23BMarket Cap
LossP/E TTM
After-hours 17:10 (ET)28.460USD+0.050+0.18%
After-hours 17:10 (ET)Today
-0.21%
5 Days
+15.48%
1 Month
+55.85%
6 Months
+67.59%
Year to Date
-8.45%
1 Year
+3.83%
Key Figures
28.660Open
29.470High
367.54KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.32%Turnover Ratio
28.550Prev. Close
27.860Low
10.49MTurnover
LossP/E Static
6.67P/B
0.00%Div Yield TTM
-49.74%ROA
34.29052wk High
0.08Volume Ratio
-269.95MNet Profit
113.29MShares
-3.9978EPS TTM
0.88Beta
-78.43%ROE
13.18052wk Low
6.09%Amplitude
94.17%Gross Margin
3.23BMarket Cap
5.81Reward/Risk
4.53%Risk Rate
Viridian Therapeutics Inc's Score
0.12vs previous score
Forecast8.71
Financial Health6.77
Technical6.16
Valuation Dimensions7.64
Institutional Confidence10.00
Risk Assessment5.93
Media Coverage
Coverage Level
Very Low
Very High
No data
Analyst Rating
Viridian Therapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Strong buy
Viridian Therapeutics Inc Latest Earnings Call Transcripts
Viridian Therapeutics (VRDN) Q3 2026 Earnings Call: Lumvoa Revenue Reaches $24.7 Million
Viridian Therapeutics’ Q3 2026 earnings call covered $24.7 million in Lumvoa revenue, more than 100 patient starts, payer access and pipeline milestones.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.89/-0.97
Revenue / Forecast
25.75M/5.08M
Viridian Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolVRDN
Number of employees143
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 11.24% |
| BlackRock Institutional Trust Company, N.A. | 5.03% |
| Deep Track Capital LP | 4.91% |
| Bellevue Asset Management AG | 3.95% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 41.90% |
| Hedge Fund | 24.54% |
| Investment Advisor/Hedge Fund | 21.23% |
| Venture Capital | 7.32% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of Viridian Therapeutics Inc (VRDN)?
The current price of Viridian Therapeutics Inc (VRDN) is 28.49.
What is the symbol of Viridian Therapeutics Inc?
The ticker symbol of Viridian Therapeutics Inc is VRDN.
What is the 52-week high of Viridian Therapeutics Inc?
The 52-week high of Viridian Therapeutics Inc is 34.29.
What is the 52-week low of Viridian Therapeutics Inc?
The 52-week low of Viridian Therapeutics Inc is 13.18.
What is the market capitalization of Viridian Therapeutics Inc?
The market capitalization of Viridian Therapeutics Inc is 3.23B.
Is Viridian Therapeutics Inc (VRDN) currently rated as Buy, Hold, or Sell?
According to analysts, Viridian Therapeutics Inc (VRDN) has an overall rating of Buy, with a price target of 36.20.
What is the Earnings Per Share (EPS TTM) of Viridian Therapeutics Inc (VRDN)?
The Earnings Per Share (EPS TTM) of Viridian Therapeutics Inc (VRDN) is -4.00.